HBV相关的原发性肝透明细胞癌组织CK19表达及其临床意义*

doi:10.3969/j.issn.1672-5069.2015.06.017

Abstract

Abstract: Objective To investigate the expression of cytokeratin-19（CK19） in primary liver clear cell carcinoma（PCCCL） and explore its implication for prognosis of patients with PCCCL. Methods The liver cancerous tissues from 76 individuals with HBV-associated PCCCL from 2006 to 2014 in Beijing You`An Hospital affiliated to Capital Medical University were retrospectively reviewed. The expressions of CK19,P53,CD34, glypican-3 （GPC-3）,HepPar-1 were detected by immunohistochemistry staining. Kaplan-Meier survival curves and Wilcoxon test were used to assess the prognosis between CK19-positive and negative patients. Results 9 （11.84%） out of 76 patients with PCCCL were found CK19 positive in tumor tissues;When tumors were greater than 3 cm,a distant metastasis were 60.0%（3/5） in CK19 positive cases,which was much higher than 8.7%（2/23,P<0.05）in CK19 negative cases;The patients with CK19 negative had longer （60 weeks） survival times than in patients with CK19 positive（31 weeks,P<0.05） as showed by the Kaplan-Meier survival curves and Wilcoxon tests. Conclusion PCCCL consists of a heterogeneous origin,and it may transformed from CK19 positive hepatic progenitor cells in the process of differentiation and maturation. The expression of CK19 in PCCCL is closely associated with the poor prognosis of patients with PCCCL.

Key words: Primary clear cell carcinoma of liver, Cytokeratin-19, Prognosis

Che Ruiwen， Feng Shuai， Feng Jiliang， et al.. Expression of cytokeratin-19 in cancerous tissues of patients with hepatitis B-associated primary clear cell carcinoma of liver[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(6): 633-637.

References

[1] Fléjou JF. WHO classification of digestive tumors:the fourth edition. Ann Pathol,2011,31（5）:27-31.
[2] Li T,Fan J,Qin L X,et al. Risk factors,prognosis,and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol,2011,18（7）:1955-1963.
[3] Wang H,Tan B,Zhao B,et al. CT findings of primary clear cell carcinoma of liver with analysis of 19 cases and review of the literature. Abdom Imaging,2014,39（4）:736-743.
[4] Liu Z,Ma W,Li H,et al. Clinicopathological and prognostic features of primary clear cell carcinoma of the liver. Hepatol Res,2008,38（3）:291-299.
[5] Lao X M,Zhang Y Q,Jin X,et al. Primary clear cell carcinoma of liver-clinicopathologic features and surgical results of 18 cases. Hepatogastroenterology,2006,53（67）:128-132.
[6] Lai C L,Wu P C,Lam K C,et al. Histologic prognostic indicators in hepatocellular carcinoma. Cancer,1979,44（5）:1677-1683.
[7] Ji S P,Li Q,Dong H. Therapy and prognostic features of primary clear cell carcinoma of the liver. World J Gastroenterol, 2010,16（6）:764-769.
[8] 李智宇,毕新宇,赵建军,等. 原发性透明细胞型肝细胞肝癌的临床特点及预后分析. 中华肿瘤杂志,2013,35（2）:140-143.
[9] Kim H,Choi GH,Na DC,et al. Human hepatocellular carcinomas with “Stemness”-related marker expression:keratin 19 expression and a poor prognosis. Hepatology,2011,54（5）:1707-1717.
[10] Lee C W,Kuo W L,Yu M C,et al. The expression of cytokeratin 19 in lymph nodes was a poor prognostic factor for hepatocellular carcinoma after hepatic resection. World J Surg Oncol,2013,11（1）:136-146.
[11] van Sprundel R G,van den Ingh T S,Desmet V J,et al. Keratin 19 marks poor differentiation and a more aggressive behaviour in canine and human hepatocellular tumours. Comp Hepatol,2010,9（1）:4-14.
[12] Bosman F,Cameiro F,Hmban R. WHO classification of tumors of the digestive system.4th ed. Lyonyiarc Press,2010:414-415.
[13] Zhisheng L,Weidong M,Huikai L,et al. Clinicopathological and prognostic features of primary clear cell carcinoma of the liver. Hepatol Res,2008,38（3）:291-299.
[14] Murakata LA,Ishak KG,Nzeako UC,et al. Clear cell carcinoma of the liver:A comparative immunohistochemical study with renal clear cell carcinoma. Mod Pathol,2000,13（8）:874-881.
[15] Sshupet H,Pteresen BE. Evidence regarding a stem cell origin of hepatocellular carcinoma. Stem Cell Pev,2005,1（3）:261-264.
[16] Qian Y B,Zhang J B,Wu W Z,et al. P48 is a predictive marker for outcome of post operative interferon alpha treatment inpatients with hepatitis B virus infection related hepatocellular carcinoma. Cancer,2006,107（7）:1562-1569.
[17] Takahiro U,Shoji K,Takatsugu Y,et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer,2003,94（10）:851-857.
[18] Durnez A,Verslype C,Nevens F,et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology,2006,49（2）:138-151.
[19] Wang WD,Zhao M,Li YJ,et al. Expressions and clinical significance of CD147 and CK19 in hepatocellular carcinoma. Chin German J Clin Oncol,2012,11（9）:517-521.
[20] Nishimura Y,Nakatsura T,Senju S,et al. Usefulness of a novel fetal antigen,glypican-3,for diagnosis and immunotherapy of hepatocellular carcinoma. Jap J Clin Immunol,2008,31（5）:383-391.
[21] Fasano M,Theise ND,Nalesnik M,et al. Immunohistochemical evaluation of hepatoblastomas with use of the hepatocyte-specific marker,hepatocyte paraffin 1,and the polyclonal anticarcinoembryonic antigen. Mod Pathol,1998,11（10）:934-941.

Expression of cytokeratin-19 in cancerous tissues of patients with hepatitis B-associated primary clear cell carcinoma of liver

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[2]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[3]	Zhuang Taiping, Yin Yangyan, Xie Manfang, et al. Comparison of clinical features of infants with human cytomegalovirus infection and of infantile hepatitis syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 514-517.
[4]	Peng Silu, Liu Bing, Sun Hong, et al. Prognosis of patients with hepatitis B-induced acute-on-chronic liver failure [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 545-548.
[5]	Zhang Tingting, Wang Xuan. Clinical implications of oral glucose tolerance test in cirrhotic patients with hepatogenous diabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 449-452.
[6]	Gao Pengbin, Zhao Xiaoyan, Qin Hao, Wu Fengying, Zhang Haizhen, Wang Lin, Jia Huina, Li Shujuan. Risk factors for poor prognosis of patients with hepatitis E-induced liver failure [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 220-223.
[7]	Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana. Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 248-251.
[8]	Zhang Xiaozhou, Shuai Ling, Wang Qingda, Yang Nan. Changes of serum miR-335 levels in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 268-271.
[9]	Ma Deyuan, Ma Yuanfeng, Zhang Dianlong, et al.. Prognostic efficacy of serum keratin 18 in patients with hepatitis B virus-related acute on chronic liver failure [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 77-80.
[10]	Ma Lyuxiang, Zhang Xuesong.. Efficacy and prognosis of ultrasound-guided percutaneous radiofrequency ablation in treatment of patients with small hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 125-128.
[11]	Yu Xutong, Jiang Xiuhua, Qi Tingting, et al.. Verification of bleeding criteria in patients with acute-on-chronic liver failure: A prospective study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 885-889.
[12]	Hongjie, Zhou Dongfang.. Efficacy of entecavir and Chinese herbal medicine combination therapy in patients with hepatitis B-induced liver cirrhosis An [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 903-906.
[13]	Baoyan, Wang Yun, Xiang Xiaogang, et al.. Prognosis of patients with hepatocellular carcinoma and underlying hepatitis B An [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 924-927.
[14]	Huang Jianwen, Yang Youchao, Xu Changqing. et al. Prognosis of patients with primary liver cancer after radical tumor resection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 521-524.
[15]	Wang Wei, Wang Huifang, Zhai Jingming, et al. Plasma SPINK1 levels in patients with hepatocellular carcinoma and its relationship with prognosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 525-528.